Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,391.43
(
0.35%
)
US TECH 100
22,534.00
(
0.14%
)
Dow Jones
45,514.34
(
0.77%
)
Brent Oil
107.49
(
-0.70%
)
Bitcoin
67,432.22
(
2.24%
)
News Focus
News Focus
Post# of 257307
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122821
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 205362

Thursday, 10/20/2016 10:02:42 AM

Thursday, October 20, 2016 10:02:42 AM

Post# of 257307
ADXS/MRK—Dosing during the phase-2 portion of the study:

https://www.clinicaltrials.gov/ct2/show/NCT02325557

Patients will receive ADXS31-142 and pembrolizumab [Keytruda] in combination. Dosing of ADXS31-142 will start at one dose level less than appropriate in Part A in combination with 200 mg of pembrolizumab. Dosing of ADXS31-142 will be escalated if appropriate.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today